990 related articles for article (PubMed ID: 23632029)
1. Pompe disease: early diagnosis and early treatment make a difference.
Chien YH; Hwu WL; Lee NC
Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029
[TBL] [Abstract][Full Text] [Related]
2. Gene Therapy for Pompe Disease: The Time is now.
Colella P; Mingozzi F
Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
[TBL] [Abstract][Full Text] [Related]
3. Long-term enzyme-replacement therapy (ERT) with alglucosidase alfa: Evolution of two siblings with juvenile late-onset Pompe disease.
Rafael Bretón Martínez J; Martínez AC
J Neurol Sci; 2015 Nov; 358(1-2):459-60. PubMed ID: 26279333
[No Abstract] [Full Text] [Related]
4. Newborn screening for Pompe disease: an update, 2011.
Burton BK
Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):8-12. PubMed ID: 22253219
[TBL] [Abstract][Full Text] [Related]
5. Phenotype variations in early onset Pompe disease: diagnosis and treatment results with Myozyme.
Pascual SI
Adv Exp Med Biol; 2009; 652():39-46. PubMed ID: 20225018
[TBL] [Abstract][Full Text] [Related]
6. Pompe disease in infants: improving the prognosis by newborn screening and early treatment.
Chien YH; Lee NC; Thurberg BL; Chiang SC; Zhang XK; Keutzer J; Huang AC; Wu MH; Huang PH; Tsai FJ; Chen YT; Hwu WL
Pediatrics; 2009 Dec; 124(6):e1116-25. PubMed ID: 19948615
[TBL] [Abstract][Full Text] [Related]
7. Genotype, phenotype and treatment outcomes of 17 Malaysian patients with infantile-onset Pompe disease and the identification of 3 novel GAA variants.
Chan MY; Jalil JA; Yakob Y; Wahab SAA; Ali EZ; Khalid MKNM; Leong HY; Chew HB; Sivabalakrishnan JB; Ngu LH
Orphanet J Rare Dis; 2023 Aug; 18(1):231. PubMed ID: 37542277
[TBL] [Abstract][Full Text] [Related]
8. Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy.
Chen HA; Hsu RH; Fang CY; Desai AK; Lee NC; Hwu WL; Tsai FJ; Kishnani PS; Chien YH
Front Immunol; 2024; 15():1336599. PubMed ID: 38715621
[TBL] [Abstract][Full Text] [Related]
9. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
Wang Z; Okamoto P; Keutzer J
Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
[TBL] [Abstract][Full Text] [Related]
10. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
Kishnani PS; Beckemeyer AA
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
[TBL] [Abstract][Full Text] [Related]
11. New insights into therapeutic options for Pompe disease.
Richard E; Douillard-Guilloux G; Caillaud C
IUBMB Life; 2011 Nov; 63(11):979-86. PubMed ID: 22002928
[TBL] [Abstract][Full Text] [Related]
12. The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease.
Lacaná E; Yao LP; Pariser AR; Rosenberg AS
Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):30-9. PubMed ID: 22253234
[TBL] [Abstract][Full Text] [Related]
13. Pompe Disease: New Developments in an Old Lysosomal Storage Disorder.
Meena NK; Raben N
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32962155
[TBL] [Abstract][Full Text] [Related]
14. Early administration of enzyme replacement therapy for Pompe disease: short-term follow-up results.
Hamdan MA; Almalik MH; Mirghani HM
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S431-6. PubMed ID: 19067231
[TBL] [Abstract][Full Text] [Related]
15. A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment.
Yang CF; Liu HC; Hsu TR; Tsai FC; Chiang SF; Chiang CC; Ho HC; Lai CJ; Yang TF; Chuang SY; Lin CY; Niu DM
Am J Med Genet A; 2014 Jan; 164A(1):54-61. PubMed ID: 24243590
[TBL] [Abstract][Full Text] [Related]
16. Infantile Pompe disease: clinical and genetic characteristics with an experience of enzyme replacement therapy.
Cho A; Kim SJ; Lim BC; Hwang H; Park JD; Kim GB; Jin DK; Lee J; Ki CS; Kim KJ; Hwang YS; Chae JH
J Child Neurol; 2012 Mar; 27(3):319-24. PubMed ID: 21940687
[TBL] [Abstract][Full Text] [Related]
17. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
[TBL] [Abstract][Full Text] [Related]
18. Pompe disease ascertained through The Lantern Project, 2018-2021: Next-generation sequencing and enzymatic testing to overcome obstacles to diagnosis.
Sniderman King L; Pan Y; Nallamilli BRR; Hegde M; Jagannathan L; Ramachander V; Lucas A; Markind J; Colzani R
Mol Genet Metab; 2023 May; 139(1):107565. PubMed ID: 37087815
[TBL] [Abstract][Full Text] [Related]
19. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program.
Chien YH; Chiang SC; Zhang XK; Keutzer J; Lee NC; Huang AC; Chen CA; Wu MH; Huang PH; Tsai FJ; Chen YT; Hwu WL
Pediatrics; 2008 Jul; 122(1):e39-45. PubMed ID: 18519449
[TBL] [Abstract][Full Text] [Related]
20. Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease.
De Groot AS; Desai AK; Lelias S; Miah SMS; Terry FE; Khan S; Li C; Yi JS; Ardito M; Martin WD; Kishnani PS
Front Immunol; 2021; 12():636731. PubMed ID: 34220802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
